Evotec

Aptadir Therapeutics is a biotechnology company focused on developing novel treatments for diseases associated with abnormal DNA methylation. The company's approach involves using RNA therapeutics to inhibit the function of DNMT1, an enzyme responsible for adding methyl groups to DNA. Specifically, Aptadir is working on a treatment for Myelodysplastic Neoplasms, a group of conditions that affect the bone marrow.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. By integrating human genetics, functional genomics, and advanced microscopy, the company aims to identify novel therapeutic targets. Cajal utilizes a range of cutting-edge technologies, including high-throughput functional genomics and multi-omics approaches, to screen for targets that significantly influence the progression of neurodegenerative diseases. This comprehensive methodology supports the development of precision medicine, ultimately aiding healthcare professionals in treating patients affected by these conditions.

Central Glass Germany is a chemical manufacturing firm specializing in the development and production of chemical base materials, cosmetic ingredients, and pharmaceutical intermediates. The company focuses on fine chemicals and offers a range of services including synthesis research, process development, regulatory support, stability studies, and clinical development. Their expertise serves various industries, including pharmaceuticals, cosmetics, and food, positioning them as a key player in the chemical sector.

Rigenerand Srl is a biomedical company based in Medolla, Italy, established in 2009 by Prof. Massimo Dominici and Prof. Pierfranco Conte. It specializes in the development and production of devices that support the culture of stem cells for both pre-clinical and clinical applications. The company focuses on enhancing the ex-vivo phase of stem cell expansion by utilizing innovative biocompatible materials to achieve high cell yields. Rigenerand's product pipeline includes various reabsorbable biomaterials for tissue engineering, improved transport systems for direct stem cell delivery to patients, and 3D cell culture systems designed for drug discovery and delivery. The company's technology emerges from a collaboration between a biomedical firm and researchers from the University of Modena and Reggio Emilia.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at addressing life-threatening diseases. Utilizing its proprietary Alphamer technology, Centauri creates chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the body's immune response. The company's dual-action approach involves directly targeting cell surface antigens while employing a glycan effector domain to stimulate a robust polyclonal immune response. This mechanism promotes cell death via enhanced complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has demonstrated strong pre-clinical results, showcasing significant improvements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, as well as in vivo proof-of-concept data across various infection models.

IMIDomics is a company focused on addressing Immune-Mediated Inflammatory Diseases (IMIDs) through innovative approaches in biomarker discovery and treatment monitoring. By leveraging the world's largest IMID biobank, along with extensive clinical expertise and advanced genomic analysis, IMIDomics aims to enhance patient care. The company has developed an analytical software platform that extracts valuable insights from vast amounts of molecular and clinical data, making it accessible for healthcare professionals without requiring specialized bioinformatics knowledge. This facilitates optimized treatment strategies for IMID patients. Headquartered at Vall d'Hebron Hospital in Barcelona, Spain, and with a presence at the HudsonAlpha Institute in Huntsville, Alabama, IMIDomics is positioned at the forefront of research and application in the field of immune-mediated diseases.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

OxVax Ltd. is a spin-out company from the University of Oxford dedicated to developing an advanced dendritic cell vaccine platform aimed at treating solid tumor cancers. The company's innovative technology utilizes induced pluripotent stem cells (iPSC) to generate CD141+ dendritic cells, a unique subset that presents promising properties for cancer immunotherapy. This approach seeks to provide effective treatment options for patients with intractable cancers, leveraging the potential of dendritic cells to enhance the immune response against tumors.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Argobio is a start-up studio focused on developing innovative therapeutic solutions and fostering the growth of biotech firms. It collaborates with leading European academic research institutes to identify and nurture early-stage projects, particularly in the areas of rare diseases, neurological disorders, oncology, and immunology. By providing financial support and operational expertise, Argobio aims to cultivate these projects before launching them as independent companies. The studio also seeks to create promising platform technologies that can lead to new therapeutic products, thereby enhancing the drug research and development process for startups in the biotechnology sector.

Blacksmith Medicines is focused on developing innovative therapies that target metal-dependent enzymes, known as metalloenzymes, which play a crucial role in human physiology. With over 30% of known enzymes classified as metalloenzymes, they encompass all major enzyme classes, including oxidoreductases, transferases, and hydrolases. Blacksmith Medicines utilizes a specialized platform that combines a curated library of metal-binding pharmacophores with advanced computational modeling techniques. This approach allows for the rapid and systematic design of small molecule inhibitors that specifically interact with key metal ions within the enzyme's active site. The company's efforts are particularly directed towards creating medicines for immuno-oncology and inflammatory diseases, offering the potential for more effective and selective therapeutic options.

Autobahn Labs is a biotechnology company based in Palo Alto, California, focused on accelerating the development of novel therapeutics. Founded in 2018, it operates as a collaboration between an investor syndicate led by Samsara BioCapital and Evotec. The company identifies promising early-stage academic research projects and leverages Evotec's expertise in drug discovery and development, combined with Samsara's investment approach, to enhance patient health. Autobahn Labs provides acceleration services that include a dedicated team with deep scientific and operational knowledge, industrialized drug discovery capabilities, and funding to help research institutions advance their projects to preclinical drug candidates. Through these efforts, Autobahn Labs aims to transform innovative science into effective therapies for patients.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through nanotechnology. The company develops a pipeline of next-generation nano-formulated drugs that improve the bioavailability of poorly water-soluble medications. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates either polymeric or crystalline nanoparticles designed to offer significant differentiation and added benefits for patients. In addition to its drug development efforts, the company provides services that support pre-clinical and clinical stage formulations for clients, including new chemical entities and established branded drugs. Through its innovative approach, Leon Nanodrugs aims to improve patient outcomes in the pharmaceutical industry.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Breakpoint Therapeutics GmbH, located in Hamburg, Germany, specializes in the discovery and development of innovative anti-cancer drugs. The company focuses on targeting the DNA damage response (DDR) in cancer cells, specifically aiming to disrupt pathways related to DNA repair and replication stress tolerance. By doing so, Breakpoint Therapeutics seeks to advance first-in-class oncology drugs that not only complement existing treatments, such as PARP inhibitors, but also address the challenge of therapy-resistant cancers. Through its research and development efforts, the company aspires to enhance treatment options for patients facing difficult-to-treat cancer types.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at enhancing global access to biotherapeutics. The company focuses on innovative and integrated technologies that streamline the design, development, and manufacturing processes of biologics. Its key strengths lie in antibody discovery, molecular design, and the design of manufacturing processes and facilities. By leveraging scientific expertise and machine learning-driven technologies, Just Evotec Biologics provides clients with comprehensive solutions that accelerate biotherapeutic development while significantly lowering manufacturing costs.

Celmatix Inc. is a personalized medicine company focused on women's health, particularly in reproductive health and fertility. The company offers POLARIS, a web-based analytics platform designed to optimize a woman's fertility by assessing her likelihood of success with various treatment options based on individual clinical metrics. Additionally, Celmatix provides NOVA, a patient portal that enhances the clinic experience for patients. By leveraging predictive analytics and genomics, the company develops products that empower women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has established a strategic alliance with Evotec and is recognized for possessing the largest structured dataset on ovarian health and outcomes globally. Founded in 2009 and headquartered in New York, Celmatix is also involved in innovative research areas such as ovarian senescence and non-hormonal contraceptives.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Aptuit, LLC offers a comprehensive range of integrated drug development services tailored for the pharmaceutical industry, spanning from early discovery to mid-phase development. The company's expertise encompasses drug design, active pharmaceutical ingredient (API) development and manufacturing, solid-state chemistry, and regulatory programs that support preclinical and Investigational New Drug (IND) submissions. With facilities located in the UK, Italy, and Switzerland, Aptuit provides its biopharma partners with synergistic scientific capabilities across drug discovery, preclinical testing, and both drug substance and product manufacturing. This integrated approach enables efficient solutions and accelerates the translation of drugs into clinical trials. Aptuit is also backed by Welsh, Carson, Anderson & Stowe, a prominent private equity investor.

Forge Therapeutics, Inc. is a biotechnology company focused on discovering and developing innovative therapeutics through a unique chemistry platform that targets metalloproteins. The company specializes in creating novel antibiotics aimed at combating multi-drug resistant bacteria. By employing a proprietary approach that combines bioinorganic and medicinal chemistry, Forge develops selective small molecule inhibitors that target metalloenzymes, particularly in gram-negative bacteria. This strategy enables healthcare professionals to effectively access various biochemical processes and biological catalysis essential for treating challenging diseases.

Eternygen GmbH is a biotechnology company based in Berlin, Germany, with an additional office in the United Kingdom. Founded in June 2012, the company specializes in the research and development of innovative drugs aimed at treating dietary-related metabolic diseases, which have seen a significant rise in prevalence over recent decades. Eternygen focuses on small molecule inhibitors targeting the sodium-coupled citrate transporter (NaCT), a crucial regulator of lipid metabolism linked to conditions such as fatty liver, diabetes, and obesity. By addressing the underlying metabolic failures associated with these diseases, Eternygen aims to develop safe and effective therapies that can enhance patient care in managing these widespread health issues.

Cyprotex PLC is a provider of preclinical ADME Tox services, focusing on absorption, distribution, metabolism, excretion, and toxicity/pharmacokinetic information for pharmaceuticals and other chemicals. Founded in 1999 and headquartered in Macclesfield, United Kingdom, the company delivers a wide range of in vitro and in silico services. Its offerings include metabolism studies, permeability assessments, toxicology evaluations, and physicochemical profiling, alongside custom assay development. Cyprotex uses advanced modelling approaches to predict human pharmacokinetics and toxicity from chemical structures, catering to pharmaceutical, biotechnology, cosmetics, agrochemical, and academia sectors. The company plays a critical role in enhancing drug safety and efficacy predictions, ensuring compliance with regulatory standards for its diverse clientele in Europe, North America, and internationally.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Sanofi Oncology, a division of global healthcare company Sanofi, focuses on developing and delivering innovative treatments for various types of cancer. With a rich heritage in oncology, Sanofi Oncology leverages its extensive knowledge base to research and treat cancer from multiple angles, addressing diverse patient needs and disease stages. The company's portfolio includes therapies for rare diseases, immunology, and cardiovascular conditions, among others. Sanofi's commitment to patients drives its strategy to create long-term value through innovative treatments, from research and development to manufacturing and marketing.

Euprotec is a preclinical contract research organization that specializes in providing research services to companies engaged in the discovery and development of new drugs. The organization focuses on therapeutic areas such as infections, respiratory diseases, and allergies, offering expertise to support the research and development processes of its clients. By collaborating with pharmaceutical and biotechnology firms, Euprotec plays a critical role in advancing the development of innovative treatments in these key medical fields.

Bionamics GmbH is an asset management company based in Hamburg, Germany, specializing in the management of life science assets. The firm focuses on bridging the gap between outstanding research projects and the pharmaceutical industry's requirements for pre-clinical and clinical development programs. Bionamics offers project management services to pharmaceutical companies, facilitating the acquisition and licensing of life science assets in their early stages. By connecting innovative research with industry needs, Bionamics plays a vital role in advancing drug development and enhancing therapeutic options.

Cell Culture Service GmbH (CCS), a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies. CCS is one of the leading suppliers of custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes, and proteins for high throughput screening with more than ten years experience in bulk cell production.

Compound Focus, Inc. offers molecule compound management services for liquid and solid compounds.

KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. They are a service company specializing in chemical proteomics methods to support the successful development of small molecule drugs. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, they continuously expand and improve their technology platform in collaboration with the leading Max Planck laboratories of Axel Ullrich, Henrik Daub and Matthias Mann. KINAXO offers its clients extensive experience in cellular target profiling and other chemical proteomics applications.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Evotec (India) Private Limited provides drug discovery and development services for pharmaceutical, biotech, and fine chemical industries.

Renovis, Inc. is a biopharmaceutical company focused on the development of drugs for neurological diseases and disorders. The company is actively working on treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing a range of scientific disciplines, including molecular biology, medicinal chemistry, pharmacology, drug metabolism, toxicology, and informatics, Renovis aims to identify and select small molecule drug candidates that adhere to rigorous development standards.

Evotec Neurosciences GmbH is a biotechnology company focused on the discovery and development of small molecule drugs aimed at treating Alzheimer's disease and other neurological disorders. Through its research initiatives, the company seeks to create innovative therapeutics that address significant unmet medical needs in the field of neuroscience.

Oxford Asymmetry International serves as an outsourcing partner for the pharmaceutical, biotechnology, and agrochemical sectors. The company specializes in chemical discovery and development services, focusing on the creation of chiral chemicals and advanced organic compounds. Through its various divisions, Oxford Asymmetry International utilizes organic chemistry, polymer technologies, and automation to provide compounds for screening. This comprehensive approach enables clients to enhance and expedite their chemistry processes, facilitating innovation and development within their respective industries.